Biosimilars: Global Markets

Report Highlights

The global biosimilars market was valued at $23.8 billion in 2023. The market is expected to grow from $28.5 billion in 2024 to $69.2 billion by 2029, at a compound annual growth rate (CAGR) of 19.4% from 2024 through 2029.

Report Includes

• 142 data tables and 74 additional tables
• An analysis of the global market trends for biosimilars, with historic revenue data (sales figures) from 2021 and 2022, estimates for 2023, forecast for 2024, and projected CAGRs through 2029
• Estimates of the market size and revenue growth prospects, along with a market share analysis by product type and sub-type, therapeutic application, and region
• Facts and figures pertaining to the market dynamics, advances in existing biosimilars, regulations and the impact of macroeconomic factors
• Review of the industry structure, emerging trends and developments, clinical trials and approvals, and new product
• Insights derived from the Porter’s Five Forces model, as well as global supply chain and PESTLE analyses
• An analysis of key patent publications, grants and applications in biosimilars
• Analysis of the competitive landscape featuring companies’ market shares, strategic alliances, M&A activity and a venture funding outlook
• Overview of sustainability trends and ESG developments, with emphasis on consumer attitudes, and ESG scores and practices of leading companies
• Profiles of the market leaders, including Amgen Inc., Sandoz Group AG, Biocon Biologics Ltd., Pfizer Inc., and Teva Pharmaceutical Industries Ltd.

Report Scope

This report provides the current and future market potential of biosimilars, with market projections through 2029; and it includes a detailed analysis of the drivers, restraints and opportunities in the biosimilars market. The report also covers the competitive environment of the biosimilars industry and features a product analysis.

For this analysis, the market for biosimilars is segmented based on product type, therapeutic application and region. Based on product type, it is segmented into monoclonal antibodies, recombinant growth factors, recombinant hormones, fusion protein and others (such as LMWHs and interferons). Based on therapeutic application, the market is segmented into the following: cancer and related disorders, autoimmune and inflammatory diseases, diabetes, anemia, growth hormone deficiency and other diseases. Based on geographical region, the biosimilars market is segmented into the following: North America, Europe, Asia-Pacific and the Rest of the World (RoW). The North American region includes the U.S., Canada and Mexico. Europe includes Germany, the U.K., Italy, France, Spain and the Rest of Europe; Asia-Pacific includes China, Japan, India, Australia, South Korea and the Rest of Asia-Pacific. For market estimate data, 2021 and 2022 serve as the historical years, 2023 as the base year, and 2029 as the forecast year.

The report provides company profiles of key players in the biosimilars market that feature detailed information about each organization’s business segments, financials, product portfolios and recent developments.

Analyst Credentials

BCC Research Team possesses expertise and experience in life and physical science domains. They specialize in offering valuable business insights, including industry analysis, competitor intelligence, strategic and financial analysis, and opportunity assessment. The team has in-depth knowledge of various sectors, including healthcare, biotechnology, pharmaceuticals, IT, automation, advanced materials, and energy. They are proficient in qualitative and quantitative market intelligence providing clients with actionable insights. With a vast understanding of the competitive landscape, the team can support clients in making data-driven decisions to help them achieve a competitive edge in their respective markets.

Consulting Editor’s Credentials

Mariana Kuznietsova, a Life Science Consultant at BCC Research, has 8 years of experience in both academic and industry research developing biochemical and biotechnological applications and laboratory services. She also has a strong background in laboratory equipment trading services covering technical support, complex lab solutions to meet demands of laboratories from a range of areas, such as Academia, Agriculture, Pharma, and Food and Beverage. Mariana holds a Ph.D. in Biochemistry from the Taras Shevchenko National University of Kyiv, Ukraine.